Nootropic & CNS

Definition

Nootropic and CNS peptides modulate neurotransmitter systems, neurotrophin signaling, and neuroprotective pathways to enhance cognitive function, reduce anxiety, or support neurological recovery. Most compounds in this category emerged from Soviet and Russian neuropeptide research programs active from the 1970s through the 1990s — programs that produced drugs now prescribed routinely in Russia, Ukraine, and Eastern Europe, but rarely studied in Western clinical trials. This creates an unusual evidence profile: real drug products with decades of clinical use data, but limited access to Western-format RCT literature.

Mechanism of Action

Semax is a synthetic heptapeptide based on the ACTH 4–7 fragment, modified for intranasal delivery. It upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), increases dopaminergic and serotonergic tone, and reduces oxidative stress in neural tissue. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) acts on the GABAergic and serotonergic systems, producing anxiolytic effects comparable to benzodiazepines in animal models without dependence. It also modulates BDNF and enkephalin expression. Cerebrolysin is a porcine-derived peptide mixture (molecular weight < 10,000 Da) that mimics the action of multiple neurotrophic growth factors including NGF, BDNF, GDNF, and CNTF. Cortexin is a cortical polypeptide extract with broad neuroprotective, nootropic, and anticonvulsant activity.

Regulatory Status

Semax and Selank are registered pharmaceutical drugs in Russia (Semax: ЛС-000297; Selank: ЛС-001027). Cerebrolysin is approved in 50+ countries for stroke rehabilitation and Alzheimer's disease. Cortexin is an approved drug in Russia for neurological conditions. None are FDA-approved. Available in the US through research suppliers; some compounding pharmacies have begun offering intranasal preparations of Semax and Selank.

Evidence Base

The evidence base is substantial in total volume but skewed toward non-Western trials. Cerebrolysin has the most internationally recognized data: independent Cochrane reviews and meta-analyses support modest benefit in acute ischemic stroke rehabilitation. A Phase IV multinational RCT (CASTA) confirmed functional improvement. Semax has Russian Phase II/III data in stroke and cognitive decline. Selank's anxiolytic data is primarily from Russian trials and animal studies. This is a category where the evidence is real but requires independent Western replication for full clinical acceptance. The cognitive enhancement and neuroprotective rationale is scientifically coherent.